RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 90 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $5,062,000 | -51.0% | 234,482 | -50.1% | 1.64% | -44.0% |
| Q2 2019 | $10,329,000 | -7.0% | 469,482 | +15.9% | 2.92% | -26.8% |
| Q1 2019 | $11,102,000 | +3.3% | 405,026 | +1.3% | 3.99% | -19.1% |
| Q4 2018 | $10,752,000 | -47.1% | 400,000 | -42.6% | 4.94% | -26.0% |
| Q3 2018 | $20,329,000 | -9.9% | 696,903 | -3.5% | 6.66% | -13.4% |
| Q2 2018 | $22,567,000 | +467.0% | 721,903 | +261.0% | 7.69% | +366.2% |
| Q1 2018 | $3,980,000 | -21.7% | 200,000 | +14.3% | 1.65% | -53.7% |
| Q4 2017 | $5,086,000 | – | 175,000 | – | 3.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 4,909,956 | $142,977,919 | 8.04% |
| Opaleye Management Inc. | 735,000 | $21,403,200 | 7.44% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $55,153,280 | 3.43% |
| RA Capital Management | 5,516,067 | $160,627,871 | 3.26% |
| Altium Capital Management LP | 170,000 | $4,950,400 | 2.52% |
| Samsara BioCapital, LLC | 345,293 | $10,054,932 | 2.16% |
| Rock Springs Capital Management LP | 1,760,865 | $51,276,389 | 1.23% |
| Parkman Healthcare Partners LLC | 157,862 | $4,596,941 | 1.22% |
| Baker Brothers Advisors | 6,354,608 | $185,046,185 | 1.11% |
| EAM Investors, LLC | 164,695 | $4,795,918 | 0.99% |